✦ LIBER ✦

Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer

✍ Scribed by Randall P. Rago; Albert Einstein; Richard Lush; Tomasz M. Beer; Yoo-Joung Ko; W. David Henner; Glenn Bubley; Elizabeth A. Merica; Varun Garg; Ene Ette; Matthew W. Harding; William S. Dalton

Publisher: Springer
Year: 2003
Tongue: English
Weight: 238 KB
Volume: 51
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-003-0573-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of the safety and effic

A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer

✍ Leena Gandhi; Matthew W. Harding; Marcus Neubauer; Corey J. Langer; Melvin Moore 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

A phase 3 randomized controlled trial of

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer

✍ Michael A. Carducci; Fred Saad; Per-Anders Abrahamsson; David P. Dearnaley; Clau 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 2 views

## Abstract ## BACKGROUND. The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin‐A receptor antagonist, in patients with metastatic hormone‐refractory prostate cancer (HRPC). ## METHODS. This multinational, double‐blind, placebo‐contro